A detailed history of Russell Investments Group, Ltd. transactions in Geron Corp stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 2,489,261 shares of GERN stock, worth $9.24 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,489,261
Previous 2,142,919 16.16%
Holding current value
$9.24 Million
Previous $9.09 Million 24.39%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.17 - $4.99 $1.44 Million - $1.73 Million
346,342 Added 16.16%
2,489,261 $11.3 Million
Q2 2024

Aug 08, 2024

BUY
$3.1 - $5.09 $1.22 Million - $2 Million
392,320 Added 22.41%
2,142,919 $9.09 Million
Q1 2024

May 08, 2024

BUY
$1.75 - $3.44 $898,388 - $1.77 Million
513,365 Added 41.49%
1,750,599 $5.78 Million
Q4 2023

Feb 05, 2024

BUY
$1.74 - $2.31 $356,291 - $473,007
204,765 Added 19.83%
1,237,234 $2.61 Million
Q3 2023

Nov 13, 2023

BUY
$2.11 - $3.28 $2.11 Million - $3.28 Million
999,685 Added 3049.31%
1,032,469 $2.19 Million
Q2 2023

Aug 10, 2023

BUY
$1.97 - $3.69 $47,567 - $89,098
24,146 Added 279.53%
32,784 $105,000
Q1 2023

May 09, 2023

SELL
$2.14 - $3.4 $9,366 - $14,881
-4,377 Reduced 33.63%
8,638 $18,000
Q3 2022

Nov 04, 2022

SELL
$1.67 - $2.94 $8,637 - $15,205
-5,172 Reduced 28.44%
13,015 $30,000
Q2 2022

Jul 29, 2022

SELL
$1.19 - $1.65 $10,345 - $14,345
-8,694 Reduced 32.34%
18,187 $28,000
Q4 2021

Jan 21, 2022

BUY
$1.22 - $1.72 $32,794 - $46,235
26,881 New
26,881 $32,000
Q4 2018

Feb 11, 2019

SELL
$0.98 - $1.85 $119,431 - $225,457
-121,869 Closed
0 $0
Q3 2018

Oct 26, 2018

BUY
$1.76 - $6.38 $214,489 - $777,524
121,869 New
121,869 $214,000
Q4 2017

Feb 06, 2018

SELL
$1.8 - $2.32 $655,182 - $844,456
-363,990 Closed
0 $0
Q3 2017

Nov 07, 2017

BUY
$1.99 - $2.65 $724,340 - $964,573
363,990
363,990 $794,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.4B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.